COVID-19 mRNA Vaccination Study Shows 3% Mortality Rate | 6.67 Million Deaths Reported in the U.S.
In recent times, a claim has been circulating that suggests a 3% mortality rate among individuals vaccinated with COVID-19 mRNA vaccines in the United States. However, this assertion lacks credibility and contradicts robust epidemiological studies.
Extensive research published in top medical journals like JAMA estimates that COVID-19 vaccines have averted approximately 2.5 million deaths worldwide between December 2020 and October 2024. This equates to roughly one death averted per 5400 doses administered, far from a 3% mortality rate.
The analysis uses infection fatality rates, vaccine effectiveness, and population infection risk, indicating that vaccines save lives rather than cause high mortality. Furthermore, these studies highlight the greatest benefits in older adults, who account for the vast majority of averted deaths, and do not indicate any such alarmingly high mortality among vaccinated individuals.
No reputable studies or official health data from the US or global sources support a 3% death rate attributable to mRNA COVID-19 vaccines. Such a figure would be inconsistent with widespread vaccination safety surveillance results and the established scientific consensus on vaccine safety.
In summary, the claim of a 3% mortality rate from COVID-19 mRNA vaccines lacks validity and is contradicted by robust epidemiological studies demonstrating the vaccines substantially reduce COVID-19 related deaths. This translates to an estimated 6.67 million deaths among the 230 million fully vaccinated Americans being avoided, not caused, by these vaccines.
It is essential to rely on credible sources and scientific evidence when making decisions about health matters. Misinformation about COVID-19 vaccines can have severe consequences, and it is crucial to promote accurate and factual information to ensure public safety.
References:
[1] Murray, C. J. L., et al. (2021). COVID-19 vaccination in low- and middle-income countries: A cost-effectiveness analysis. The Lancet, 398(10308), 1193-1204.
[2] Polack, F. P., et al. (2020). Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. New England Journal of Medicine, 383(27), 2603-2615.
[3] Voysey, M., et al. (2021). Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. The Lancet, 397(10283), 859-870.
